Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII |
|
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H25ClN2O2 |
Molar mass | 408.919 g·mol−1 |
3D model (JSmol) | |
| |
|
NPS-2143 (SB-262,470A) is a calcilytic drug which acts as an antagonist at the Calcium-sensing receptor (CaSR), and consequently stimulates release of parathyroid hormone.[1] Calcilytic drugs have been researched as potential treatments for osteoporosis, and as the first such compound developed, NPS-2143 is still widely used in research into the CaSR receptor as well as design of newer calcilytic agents.[2][3][4]
See also
References
- ↑ Nemeth EF, Delmar EG, Heaton WL, Miller MA, Lambert LD, Conklin RL, et al. (October 2001). "Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone". The Journal of Pharmacology and Experimental Therapeutics. 299 (1): 323–31. PMID 11561095.
- ↑ Marquis RW, Lago AM, Callahan JF, Trout RE, Gowen M, DelMar EG, et al. (July 2009). "Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues". Journal of Medicinal Chemistry. 52 (13): 3982–93. doi:10.1021/jm900364m. PMID 19492813.
- ↑ Kiefer L, Leiris S, Dodd RH (May 2011). "Novel calcium sensing receptor ligands: a patent survey". Expert Opinion on Therapeutic Patents. 21 (5): 681–98. doi:10.1517/13543776.2011.568479. PMID 21406038. S2CID 27608531.
- ↑ Breitwieser GE (May 2014). "Pharmacoperones and the calcium sensing receptor: exogenous and endogenous regulators". Pharmacological Research. 83: 30–7. doi:10.1016/j.phrs.2013.11.006. PMID 24291533.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.